EDAP TMS SA (FOCL) Form 424B5 — Aug 12, 2026
EDAP TMS S.A., now operating as FocalTherics under Nasdaq ticker FOCL, is selling 8,425,000 American Depositary Shares at $4.75 per ADS in an underwritten follow-on, expecting net proceeds of approximately $37.1 million and up to roughly $42.7 million if underwriters exercise their 1,263,750-ADS option in full. Settlement is expected on or about August 14, 2026. The $4.75 price is about 21% below the $6.01 close on August 11, 2026, and new investors face immediate dilution of $3.82 per ADS. Ordinary shares outstanding rise from 37.48 million to approximately 45.9 million, or 47.2 million with the option.
Key figures
- Gross Proceeds
- 40018750
- Offering Price
- 4.75
- Shares Offered
- 8425000
- Shares Outstanding
- 37,481,986 ordinary shares as of March 31, 2026; 45,906,986 after offering (47,170,736 if underwriters' option exercised in full)
- Cash Runway
- cash, cash equivalents and short-term investments sufficient through Q2 2027 excluding offering proceeds
- Net Proceeds
- approximately $37.1 million ($42.7 million if greenshoe exercised in full)
- Greenshoe Adss
- 1263750
- Shelf Capacity
- US$125,000,000 Form S-3 shelf (effective March 31, 2026)
- Settlement Date
- on or about August 14, 2026 (T+2)
- Lockup Period Days
- 90
- Last Reported Sale Price
- $6.01 per ADS on August 11, 2026
- Proceeds Before Expenses
- $37,617,625 ($43,260,268.75 with option)
- Estimated Offering Expenses
- approximately $0.5 million
- Director Officer Indications
- up to $550,000 of ADSs
- Net Tangible Book Value Per Ads
- $0.15 as of March 31, 2026; $0.93 pro forma after offering
- Underwriting Discount Per Ads
- $0.285 ($2,401,125 total; $2,761,293.75 with option)
- Dilution Per Ads To New Investors
- $3.82
- Offering Price Discount To Last Close
- approximately 21%
Price after filing
Close on the filing date to close N calendar days later (from $4.75). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.